文献速递妇科产科

维利帕尼(ABT-888)联合低剂量分次全腹放疗治疗晚期实体恶性肿瘤及腹膜癌病的I期研究最终报告:在卵巢癌和输卵管癌患者中进行剂量递增

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
PubMed 文献 · Gynecol Oncol · 2017-01-18

这项I期研究将维利帕尼(40-400mg口服,每日两次,每28天周期用21天,共3周期)与低剂量分次全腹放疗(每周期第1-3周的第1天和第5天,每日两次0.6Gy,共36次21.6Gy)联合,治疗32例晚期实体恶性肿瘤及腹膜癌病患者,其中卵巢癌和输卵管癌患者参与剂量递增。最大耐受剂量为250mg口服每日两次,常见3-4级毒性为淋巴细胞减少(59%),中位无进展生存期3.6个月,中位总生存期9.1个月,仅观察到1例客观缓解(3%),见于胚系BRCA突变且铂敏感患者。

要点

  • 维利帕尼联合低剂量分次全腹放疗的最大耐受剂量为250mg口服每日两次。
  • 常见3-4级治疗相关毒性包括淋巴细胞减少(59%)、贫血(9%)、血小板减少(12%)。
  • 中位无进展生存期3.6个月,中位总生存期9.1个月,仅1例客观缓解(3%)。

核心结论

  • 维利帕尼联合低剂量分次全腹放疗可耐受,最常见毒性为胃肠道症状、疲乏和骨髓抑制。
  • 唯一观察到的客观缓解见于胚系BRCA突变且铂敏感的患者。

研究设计与样本

  • I期剂量递增研究,共治疗32例晚期实体恶性肿瘤及腹膜癌病患者。
  • 维利帕尼40-400mg口服每日两次,每28天周期第1-21天给药,共3周期,设6个剂量水平。
  • 剂量水平5和6仅纳入卵巢癌和输卵管癌患者。
  • 低剂量分次全腹放疗为21.6Gy分36次,每周期第1-3周的第1天和第5天每日两次0.6Gy。
  • 中位随访45个月(范围10-50个月)。

主要发现

  • 最常见3-4级治疗相关毒性为淋巴细胞减少(59%)、贫血(9%)、血小板减少(12%)、中性粒细胞减少(6%)、白细胞减少(6%)、恶心(6%)、腹泻(6%)、厌食(6%)、呕吐(6%)和疲乏(6%)。
  • 最大耐受剂量为250mg口服每日两次。
  • 中位无进展生存期3.6个月,中位总生存期9.1个月。
  • 卵巢癌患者中,铂敏感者总生存期10.9个月,铂耐药者5.8个月。
  • 18例卵巢癌患者中14例已知胚系BRCA状态,其中5例为BRCA突变携带者;观察到1例客观缓解(3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of low-dose radiation therapy with PARP inhibition enhances anti-tumor efficacy through potentiating DNA damage. We combined low-dose fractionated whole abdominal radiation (LDFWAR) with ABT-888 in patients with peritoneal carcinomatosis with a dose escalation in ovarian and fallopian cancer patients (OV). METHODS: Patients were treated with veliparib, 40-400mg orally BID on days 1-21 of 3 28-day cycles on 6 dose levels. Dose levels 5 and 6 included only OV patients. LDFWAR consisted of 21.6Gy in 36 fractions, 0.6Gy twice daily on days 1 and 5 for weeks 1-3 of each cycle. Circulating tumor material and quality of life were serially assessed. RESULTS: 32pts were treated. Median follow-up was 45months (10-50). The most common treatment-related grade 3 and 4 toxicities were lymphopenia (59%), anemia (9%), thrombocytopenia (12%), neutropenia (6%), leukopenia (6%), nausea (6%), diarrhea (6%), anorexia (6%), vomiting (6%) and fatigue (6%). The maximum tolerated dose was determined to be 250mg PO BID. Median PFS was 3.6months and median OS was 9.1months. In OV patients, OS was longer for platinum-sensitive patients (10.9mo) compared to platinum-resistant patients (5.8mo). QoL decreased for all groups during treatment. Germline BRCA status was known for 14/18 patients with OV cancers, 5 of whom were BRCA mutation carriers. One objective response (3%) was observed. CONCLUSION: ABT-888 plus LDFWAR is tolerable with gastrointestinal symptoms, fatigue and myelosuppression as the most common toxicities. The single observed objective response was in a germline BRCA mutated, platinum-sensitive patient.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Reiss KA, Herman JM, Armstrong D, et al. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol. 2017. PMID: 28109627. doi:10.1016/j.ygyno.2017.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。